Theraclone Sciences
Theraclone Sciences specializes in rapid identification of human monoclonal antibodies through comprehensive screening technology. With over a decade of platform development, they focus on discovering antibodies for therapeutic development. They have licensed their HIV broadly neutralizing antibodies to Gilead and their platform technology to OncoResponse for oncology applications.
Industries
Nr. of Employees
small (1-50)
Theraclone Sciences
Seattle, Washington, United States, North America
Patents
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-12312396-B2
View DetailsMonoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-12018067-B2
View DetailsMethods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
US-11845789-B2
View DetailsMonoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-11584789-B2
View DetailsMethods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
US-11319362-B2
View DetailsMonoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-10865234-B2
View Details
Monoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-12312396-B2
View DetailsMonoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-12018067-B2
View DetailsMethods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
US-11845789-B2
View DetailsMonoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-11584789-B2
View DetailsMethods of treating HIV-1 infection utilizing broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibodies
US-11319362-B2
View DetailsMonoclonal antibodies directed against trimeric forms of the HIV-1 envelope glycoprotein with broad and potent neutralizing activity
US-10865234-B2
View DetailsProducts
Fully human broadly neutralizing antibodies against HIV
A set of fully human broadly neutralizing antibodies directed at HIV, identified via the company's discovery platform and licensed to an external developer for use in an HIV cure regimen.
Antibody discovery platform (licensed)
Platform for discovering human monoclonal antibodies that has been licensed to external organizations for application in therapeutic areas such as oncology.
Fully human broadly neutralizing antibodies against HIV
A set of fully human broadly neutralizing antibodies directed at HIV, identified via the company's discovery platform and licensed to an external developer for use in an HIV cure regimen.
Antibody discovery platform (licensed)
Platform for discovering human monoclonal antibodies that has been licensed to external organizations for application in therapeutic areas such as oncology.
Services
Licensing of an antibody discovery platform to external developers for use in therapeutic discovery programs.
Licensing of discovered fully human antibody candidates to third-party developers for therapeutic development.
Licensing of an antibody discovery platform to external developers for use in therapeutic discovery programs.
Licensing of discovered fully human antibody candidates to third-party developers for therapeutic development.
Expertise Areas
- Human monoclonal antibody discovery
- Broadly neutralizing antibody identification (HIV)
- Antibody screening platform development
- Technology licensing and partnering
Key Technologies
- Antibody discovery platforms
- High-throughput antibody screening and isolation
- Human monoclonal antibody isolation workflows
- Platform-based therapeutic lead identification